# Superluminal Medicines **Source:** https://geo.sig.ai/brands/superluminal-medicines **Vertical:** Healthcare **Subcategory:** General **Tier:** Leader **Website:** superluminalrx.com **Last Updated:** 2026-04-14 ## Summary Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics. ## Company Overview Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022. Superluminal's AI GPCR drug discovery platform addresses the conformational complexity that makes most GPCRs undruggable by conventional methods: GPCRs are membrane proteins that exist in multiple conformational states — their three-dimensional structure changes dynamically based on which signaling pathways are active, making it difficult to design small molecules that selectively bind one conformation (the therapeutically relevant one) without hitting off-target conformations that cause side effects. Superluminal's combination of AI-predicted protein dynamics (modeling GPCR conformational states across time), structural biology validation (cryo-EM and crystallography data to confirm binding modes), and generative chemistry (designing molecules that exploit the predicted binding pockets) enables rational drug design for GPCR targets that structure-based drug design methods fail on because the relevant binding conformation doesn't crystallize easily. In 2025, Superluminal competes in the AI drug discovery, GPCR therapeutics, and cardiometabolic drug development market with Schrödinger (NASDAQ: SDGR, computational drug design platform, $200M revenue), Recursion (NASDAQ: RXRX, AI drug discovery at scale, $400M+ raised), and Relay Therapeutics (NASDAQ: RLAY, protein dynamics drug design, $700M raised) for pharmaceutical partner AI-driven small molecule drug discovery and GPCR target development collaboration. Eli Lilly's $1.3B collaboration (in August 2025) validates Superluminal's platform at the highest tier of pharmaceutical partnership investment. NVIDIA NVentures' participation reflects AI computational infrastructure investment in the drug discovery application. RA Capital's Series A leadership provides deep biotech public market expertise. The 2025 strategy focuses on advancing the MC4R obesity program to IND filing, building the GPCR discovery pipeline for additional cardiometabolic targets under the Lilly collaboration, and expanding the platform to Class B/C GPCRs in neurological and inflammatory disease areas. ## Frequently Asked Questions ### What is Superluminal Medicines? Superluminal Medicines is a biotechnology company that uses AI, structural biology, and protein dynamics to discover drugs targeting G protein-coupled receptors (GPCRs), focusing on obesity and cardiometabolic diseases. ### What are GPCRs and why are they important? G protein-coupled receptors (GPCRs) are the target of approximately 35% of all FDA-approved drugs. However, 70% of the 800+ GPCRs remain undruggable due to the complexity of these targets. Superluminal's platform aims to unlock this potential. ### When was Superluminal Medicines founded? Superluminal Medicines was founded in 2022 by Cony D'Cruz and Ajay Yekkirala in Boston, Massachusetts. The company launched publicly with a $33 million seed round in August 2023. ### Where is Superluminal Medicines based? Superluminal Medicines is headquartered in Boston, Massachusetts, a leading hub for biotechnology and drug discovery. ### How much funding has Superluminal raised? Superluminal has raised approximately $158 million in equity funding ($33 million seed, $120 million Series A) plus a $1.3 billion partnership agreement with Eli Lilly. ### What is Superluminal's partnership with Eli Lilly? In August 2025, Superluminal entered a $1.3 billion collaboration with Eli Lilly to discover small molecule drugs for GPCR targets in obesity and cardiometabolic diseases. Lilly was also an investor in Superluminal's Series A. ### What is Superluminal's lead drug candidate? Superluminal's lead program is a selective, biased MC4R (melanocortin 4 receptor) agonist for obesity. The compound is advancing to IND-enabling studies with human trials expected by Q4 2026. ### How does Superluminal's AI platform work? The platform integrates AI/machine learning with protein dynamics and structural biology to understand how GPCRs move and change shape, enabling design of drugs that can effectively modulate these challenging targets. ### Who are Superluminal's investors? Key investors include RA Capital Management (Series A lead), Insight Partners, NVIDIA NVentures, Eli Lilly, Catalio Capital Management, and Gaingels. ### What diseases is Superluminal targeting? Superluminal focuses on obesity and cardiometabolic diseases, initially targeting rare genetic forms of obesity and hypothalamic obesity, with potential expansion to general obesity treatment in combination with GLP-1 drugs. ## Tags healthtech, b2b, ai-powered, north-america --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*